logo

For the Inventor, By the Inventor

Ibaraki, Japan

Dna Vec Research Inc.

USPTO Granted Patents = 31

% Expired Patents = 51.6



Forward Citations = 150

Loading Chart...
Loading Chart...

57 inventors (with patents filed for the assignee):

goldMedal Mamoru Hasegawa (27 out of 37 patents)

silverMedal Yoshiyuki Nagai (8 out of 8 patents)

bronzeMedal Tsuneaki Sakata (7 out of 9 patents)

4.  Atsushi Kato (6 out of 63 patents)

5.  Akihiro Iida (6 out of 8 patents)

6.  Makoto Inoue (6 out of 10 patents)

7.  Yasuji Ueda (5 out of 8 patents)

8.  Tatsuo Shioda (5 out of 5 patents)

9.  Yoshikazu Yonemitsu (4 out of 15 patents)

10.  Fukashi Murai (4 out of 4 patents)

11.  Makoto Asakawa (4 out of 4 patents)

12.  Teruo Akuta (4 out of 5 patents)

13.  Mahito Nakanishi (4 out of 5 patents)

14.  Katsuo Takeda (4 out of 4 patents)

15.  Masanori Kobayashi (3 out of 68 patents)


Core Competencies:
RNA Viral Vectors
Gene Therapy
Immunostimulatory Cytokines
Paramyxovirus
Dendritic Cells
AIDS Virus Vaccines
Recombinant Sendai Virus
Pseudotype Retroviral Vectors
Gene Transfer
Phage Technology
Negative Strand RNA
Artificial Chromosome

31 patents:

1. 8889118 - Anticancer agent containing dendritic cell having RNA virus transferred thereinto (2014-11-18),
2. 8741650 - Methods for producing minus-strand RNA viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken β-actin promoter (2014-06-03),
3. 8217019 - AIDS virus vaccines using Sendai virus vector (2012-07-10),
4. 8211868 - Paramyxovirus vector encoding angiogenesis gene and use thereof (2012-07-03),
5. 7709621 - Vectors with modified protease-dependent tropism (2010-05-04),
6. 7521043 - Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines (2009-04-21),
7. 7510706 - Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity (2009-03-31),
8. 7442544 - Recombinant sendai virus (2008-10-28),
9. 7402427 - Vectors with modified protease-dependent tropism (2008-07-22),
10. 7323337 - Gene transfer into primate embryonic stem cells using VSV-G pseudotyped simian immunodeficiency virus vectors (2008-01-29),
11. 7314614 - Recombinant sendai virus vector for introducing exogenous genes to airway epithelia (2008-01-01),
12. 7241617 - Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci (2007-07-10),
13. 7226786 - Envelope gene-deficient Paramyxovirus vector (2007-06-05),
14. 7144579 - Paramyxoviruses comprising modified transcription start sequence (2006-12-05),
15. 7101685 - Recombinant Sendai virus (2006-09-05),
Company Overview
Dna Vec Research Inc. is a biotechnology company based in Ibaraki, Japan, specializing in the development of innovative gene delivery systems. The organization focuses on advancing research in genetic engineering and therapeutic applications, utilizing cutting-edge technologies to enhance the efficacy of gene therapies. With a commitment to scientific excellence, Dna Vec Research aims to contribute to the fields of medicine and biotechnology, addressing complex health challenges through its pioneering solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

31 Patents

#14 in Ibaraki

#2,272 in Japan

#21,284 in the World

Ibaraki, JP
Ibaraki, Japan

Dna Vec Research Inc.

Forward Citations = 150

57 inventors:

goldMedal Mamoru Hasegawa (27 out of 37 patents)

silverMedal Yoshiyuki Nagai (8 out of 8 patents)

bronzeMedal Tsuneaki Sakata (7 out of 9 patents)

4.  Atsushi Kato (6 out of 63 patents)

5.  Akihiro Iida (6 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Dna Vec Research Inc.. Retrieved from https://idiyas.com/company/dna-vec-research

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…